Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 15 | 2015 | 3022 | 1.220 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2015 | 2326 | 1.040 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2014 | 115 | 0.920 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 691 | 0.830 |
Why?
|
| Carcinoma, Papillary | 2 | 2014 | 584 | 0.750 |
Why?
|
| Kidney Medulla | 2 | 2014 | 43 | 0.550 |
Why?
|
| Biomarkers, Tumor | 12 | 2014 | 10331 | 0.540 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2014 | 19 | 0.480 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 760 | 0.480 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2014 | 86 | 0.450 |
Why?
|
| Hemangiosarcoma | 2 | 2013 | 234 | 0.450 |
Why?
|
| Pathology, Surgical | 2 | 2010 | 81 | 0.430 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 4744 | 0.420 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 107 | 0.410 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2009 | 38 | 0.350 |
Why?
|
| Diagnostic Errors | 2 | 2012 | 509 | 0.340 |
Why?
|
| SOX9 Transcription Factor | 1 | 2010 | 170 | 0.340 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2013 | 882 | 0.330 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 155 | 0.330 |
Why?
|
| Clinical Protocols | 2 | 2010 | 467 | 0.320 |
Why?
|
| Specimen Handling | 1 | 2010 | 299 | 0.310 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 7548 | 0.300 |
Why?
|
| Endothelial Cells | 1 | 2013 | 1048 | 0.290 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 436 | 0.270 |
Why?
|
| Skin Neoplasms | 3 | 2010 | 4654 | 0.260 |
Why?
|
| Kidney Tubules, Collecting | 2 | 2014 | 27 | 0.230 |
Why?
|
| Urothelium | 3 | 2014 | 254 | 0.220 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 821 | 0.220 |
Why?
|
| Nephrectomy | 3 | 2015 | 779 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2014 | 2341 | 0.150 |
Why?
|
| Young Adult | 7 | 2014 | 21445 | 0.140 |
Why?
|
| Melanoma | 2 | 2010 | 5317 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2014 | 962 | 0.140 |
Why?
|
| Biopsy | 3 | 2014 | 3443 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2012 | 1620 | 0.130 |
Why?
|
| Kidney | 3 | 2015 | 2146 | 0.130 |
Why?
|
| Urachus | 1 | 2014 | 8 | 0.130 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2014 | 21 | 0.130 |
Why?
|
| Keratin-7 | 1 | 2014 | 52 | 0.120 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2014 | 34 | 0.120 |
Why?
|
| Neprilysin | 1 | 2014 | 66 | 0.120 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.120 |
Why?
|
| Urinary Bladder | 2 | 2014 | 575 | 0.120 |
Why?
|
| Humans | 27 | 2015 | 261506 | 0.120 |
Why?
|
| Angiomyolipoma | 1 | 2013 | 31 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2015 | 148 | 0.110 |
Why?
|
| Factor VIII | 1 | 2013 | 75 | 0.110 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 157 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 4849 | 0.110 |
Why?
|
| Keratins | 1 | 2013 | 330 | 0.110 |
Why?
|
| Female | 15 | 2015 | 141928 | 0.110 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2011 | 9 | 0.100 |
Why?
|
| Male | 16 | 2015 | 123000 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 593 | 0.100 |
Why?
|
| Carotid Body Tumor | 1 | 2011 | 18 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 100 | 0.100 |
Why?
|
| Succinate Dehydrogenase | 1 | 2011 | 43 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 2232 | 0.100 |
Why?
|
| Epithelioid Cells | 1 | 2011 | 43 | 0.100 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 189 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 4892 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 690 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 864 | 0.090 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2011 | 109 | 0.090 |
Why?
|
| MART-1 Antigen | 1 | 2010 | 105 | 0.090 |
Why?
|
| Hemangioma, Capillary | 1 | 2010 | 35 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2012 | 188 | 0.090 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2010 | 82 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 361 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 70 | 0.090 |
Why?
|
| S100 Proteins | 1 | 2010 | 181 | 0.090 |
Why?
|
| Vascular Neoplasms | 1 | 2010 | 114 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2009 | 102 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2013 | 4844 | 0.080 |
Why?
|
| Sirolimus | 1 | 2013 | 814 | 0.080 |
Why?
|
| Mucins | 1 | 2009 | 285 | 0.080 |
Why?
|
| Liposarcoma | 1 | 2010 | 214 | 0.080 |
Why?
|
| Sarcoma, Ewing | 1 | 2012 | 406 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 634 | 0.080 |
Why?
|
| Adult | 9 | 2014 | 77950 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2013 | 620 | 0.080 |
Why?
|
| beta Catenin | 1 | 2011 | 688 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 829 | 0.070 |
Why?
|
| Middle Aged | 13 | 2015 | 86204 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 507 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2010 | 1335 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6207 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 10035 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2054 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1363 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2013 | 1818 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 1046 | 0.070 |
Why?
|
| Aged | 9 | 2015 | 70117 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4298 | 0.070 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 1506 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2011 | 1823 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2010 | 2967 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 3230 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 14889 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2015 | 32848 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 2014 | 414 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 7551 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10001 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 1350 | 0.050 |
Why?
|
| Sarcoma | 1 | 2011 | 1725 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 2403 | 0.040 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2011 | 3518 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 1742 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13658 | 0.040 |
Why?
|
| Vincristine | 2 | 2013 | 1511 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 1904 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2014 | 4078 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2015 | 37905 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 5437 | 0.040 |
Why?
|
| United States | 2 | 2010 | 15433 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2013 | 3005 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 5767 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 29902 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 14289 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4557 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 192 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 15862 | 0.030 |
Why?
|
| Desmoglein 3 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Uroplakin III | 1 | 2012 | 8 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2012 | 24 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 671 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 134 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2012 | 146 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2012 | 344 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 11538 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2012 | 202 | 0.020 |
Why?
|
| Everolimus | 1 | 2013 | 415 | 0.020 |
Why?
|
| SMARCB1 Protein | 1 | 2011 | 109 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 984 | 0.020 |
Why?
|
| Etoposide | 1 | 2012 | 870 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 545 | 0.020 |
Why?
|
| Lipoma | 1 | 2010 | 89 | 0.020 |
Why?
|
| CA-125 Antigen | 1 | 2011 | 226 | 0.020 |
Why?
|
| Indazoles | 1 | 2011 | 297 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 838 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 669 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 362 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1910 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 1375 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 1090 | 0.020 |
Why?
|
| Prognosis | 2 | 2014 | 21713 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 3001 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1516 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3981 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 2283 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 2432 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2173 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6009 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8865 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 4971 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5112 | 0.010 |
Why?
|
| Adolescent | 2 | 2011 | 31252 | 0.010 |
Why?
|
| Child | 2 | 2011 | 29154 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 3552 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4821 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 5270 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 14551 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 16273 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 15179 | 0.010 |
Why?
|